» Articles » PMID: 36642016

Soluble CD25 Imposes a Low-zone IL-2 Signaling Environment That Favors Competitive Outgrowth of Antigen-experienced CD25 Regulatory and Memory T Cells

Overview
Journal Cell Immunol
Publisher Elsevier
Date 2023 Jan 15
PMID 36642016
Authors
Affiliations
Soon will be listed here.
Abstract

This study focused on soluble (s)CD25-mediated regulation of IL-2 signaling in murine and human CD4 T cells. Recombinant sCD25 reversibly sequestered IL-2 to limit acute maximal proliferative responses while preserving IL-2 bioavailability to subsequently maintain low-zone IL-2 signaling during prolonged culture. By inhibiting IL-2 signaling during acute activation, sCD25 suppressed T-cell growth and inhibited IL-2-evoked transmembrane CD25 expression, thereby resulting in lower prevalence of CD25 T cells. By inhibiting IL-2 signaling during quiescent IL-2-mediated growth, sCD25 competed with transmembrane CD25, IL2Rβγ, and IL2Rαβγ receptors for limited pools of IL-2 such that sCD25 exhibited strong or weak inhibitory efficacy in IL-2-stimulated cultures of CD25 or CD25 T cells, respectively. Preferential blocking of IL-2 signaling in CD25 but not CD25 T cells caused competitive enrichment of CD25 memory/effector and regulatory FOXP3 subsets. In conclusion, sCD25 modulates IL-2 bioavailability to limit CD25 expression during acute activation while enhancing CD25T-cell dominance during low-zone homeostatic IL-2-mediated expansion, thereby 'flattening' the inflammatory curve over time.

Citing Articles

A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors.

Mata-Martinez P, Celada L, Cueto F, Saenz de Santa Maria G, Fernandez J, Terron-Arcos V J Exp Clin Cancer Res. 2025; 44(1):82.

PMID: 40038821 PMC: 11881345. DOI: 10.1186/s13046-025-03337-3.


Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults.

Bredholt G, Saevik M, Soyland H, Ueland T, Zhou F, Pathirana R Vaccine X. 2024; 20:100564.

PMID: 39403561 PMC: 11472110. DOI: 10.1016/j.jvacx.2024.100564.

References
1.
Allard-Chamard H, Mishra H, Nandi M, Mayhue M, Menendez A, Ilangumaran S . Interleukin-15 in autoimmunity. Cytokine. 2020; 136:155258. DOI: 10.1016/j.cyto.2020.155258. View

2.
Vignoli M, Ciullini Mannurita S, Fioravanti A, Tumino M, Grassi A, Guariso G . CD25 deficiency: A new conformational mutation prevents the receptor expression on cell surface. Clin Immunol. 2019; 201:15-19. DOI: 10.1016/j.clim.2019.02.003. View

3.
Pyzik M, Piccirillo C . TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol. 2007; 82(2):335-46. DOI: 10.1189/jlb.1006644. View

4.
Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M . Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017; 96(8):1241-1251. DOI: 10.1007/s00277-017-2993-y. View

5.
Nelms K, Keegan A, Zamorano J, Ryan J, Paul W . The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17:701-38. DOI: 10.1146/annurev.immunol.17.1.701. View